Abciximab Facilitates the Rate and Extent of Thrombolysis
Authors:
- Elliott M. AntmanEAElliott M. Antman
- Robert P. GiuglianoRGRobert P. Giugliano
- C. Michael GibsonCGC. Michael Gibson
- Carolyn H. McCabeCMCarolyn H. McCabe
- Patrick CoussementPCPatrick Coussement
- Neal S. KleimanNKNeal S. Kleiman
- Alec VahanianAVAlec Vahanian
- A. A. Jennifer AdgeyAAA. A. Jennifer Adgey
- Ian MenownIMIan Menown
- Hans-JürGen RupprechtHRHans-JürGen Rupprecht
- R. Van der WiekenRWR. Van der Wieken
- John DucasJDJohn Ducas
- 1 June 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (21) , 2720-2732
Abstract
Background —The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a potent and safe addition to reduced-dose thrombolytic regimens for ST-segment elevation MI. Methods and Results —Patients (n=888) with ST-elevation MI presenting −1 · min −1 ) alone or in combination with reduced doses of alteplase (20 to 65 mg) or streptokinase (500 000 U to 1.5 MU). Control patients received standard weight-adjusted heparin (70-U/kg bolus; infusion of 15 U · kg −1 · h −1 ), whereas those treated with a regimen including abciximab received low-dose heparin (60-U/kg bolus; infusion of 7 U · kg −1 · h −1 ). The rate of TIMI 3 flow at 90 minutes for patients treated with accelerated alteplase alone was 57% compared with 32% for abciximab alone and 34% to 46% for doses of streptokinase between 500 000 U and 1.25 MU with abciximab. Higher rates of TIMI 3 flow at both 60 and 90 minutes were observed with increasing duration of administration of alteplase, progressing from a bolus alone to a bolus followed by either a 30- or 60-minute infusion ( P −1 · h −1 ) heparin. TIMI 3 flow rates were significantly higher in the 50-mg alteplase plus abciximab group versus the alteplase-only group at both 60 minutes (72% versus 43%; P =0.0009) and 90 minutes (77% versus 62%; P =0.02). The rates of major hemorrhage were 6% in patients receiving alteplase alone (n=235), 3% with abciximab alone (n=32), 10% with streptokinase plus abciximab (n=143), 7% with 50 mg of alteplase plus abciximab and low-dose heparin (n=103), and 1% with 50 mg of alteplase plus abciximab with very-low-dose heparin (n=70). Conclusions —Abciximab facilitates the rate and extent of thrombolysis, producing early, marked increases in TIMI 3 flow when combined with half the usual dose of alteplase. This improvement in reperfusion with alteplase occurred without an increase in the risk of major bleeding. Substantial reductions in heparin dosing may reduce the risk of bleeding even further. Modest improvements in TIMI 3 flow were seen when abciximab was combined with streptokinase, but there was an increased risk of bleeding.Keywords
This publication has 25 references indexed in Scilit:
- Combined therapy with streptokinase and integrilinJACC, 1998
- Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarctionThe American Journal of Cardiology, 1996
- Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trialJACC, 1994
- A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trialJACC, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapyJACC, 1993
- Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thromboiysisCoronary Artery Disease, 1992
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatorJACC, 1989
- Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.Journal of Clinical Investigation, 1988